Till date, acute central serous chorioretinopathy (CSC) is a poorly understood condition characterized by retinal pigment epithelial (RPE) detachments, choroidal hyperpermeability with relative choriocapillaris hypoperfusion, and accumulation of subretinal fluid. [1, 2] Excess of glucocorticoids (exogenous or endogenous) have been strongly linked with the pathogenesis of this condition. [3, 4] Recently, a number of endocrinological abnormalities such as disruption of hypothalamic-pituitary-adrenal (HPA) axis, excessive endogenous glucocorticoids and mineralocorticoids, and renin-angiotensin-aldosterone pathway changes have been associated with the development of CSC. [5] However, development of CSC has not been reported among patients with low levels of endogenous glucocorticoids. In this report, we describe a unique case of a patient who developed a large, bullous exudative retinal detachment in the presence of low serum cortisol and suppressed HPA axis treated with oral eplerenone and paradoxically with oral hydrocortisone.
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An unusual case of multifocal central serous chorioretinopathy with low serum cortisol managed using eplerenone
Kanika Aggarwal, Aniruddha Agarwal, Vishali Gupta
In this report, we describe a rare case of a 44-year-old Asian male with acute central serous chorioretinopathy (CSC) with bullous exudative retinal detachment. Endocrinology evaluation revealed hypothalamic-pituitary-adrenal axis suppression with low serum cortisol. Furthermore, neuroimaging revealed the presence of a pituitary microadenoma. He was treated with systemic eplerenone and hydrocortisone. After 12 weeks, bullous detachment completely resolved. Our case is a unique description of acute CSC with underlying low serum cortisol levels that responded to treatment with mineralocorticoid
Case Report
A 44-year-old male presented with complaints of diminution of vision in both eyes (OU) of 15-day duration. He had history of similar complaints in the left eye (OS) 2 years back. He had been examined and was diagnosed with fibrinous CSC at another center. He had a history of using topical betamethasone ointment on the hands and feet for 1.5-2 years on a regular basis for skin allergy. He was advised to discontinue the use of topical steroids by the treating ophthalmologist followed by resolution of CSC in the OS within 6-8 weeks thereafter. However, on further questioning, he reported intermittent use of the steroid cream. He remained asymptomatic for 2 years before presenting to our center with similar visual complaints.
On examination, his best-corrected visual acuity (BCVA) was 6/9 in the right eye (OD) and 6/12 in OS. Slit-lamp biomicroscopic examination revealed the presence of multiple were within normal range. The serum electrolytes were in the normal range. At this time, the patient was advised magnetic resonance imaging (MRI) of the brain to determine the presence of any pituitary lesion. MRI brain revealed a nodular lesion on the left side of the pituitary region (3.5 × 3.9 × 4.6 mm) (microadenoma). The endocrinologist opined that the microadenoma was possibly an incidental finding and it was nonfunctional. No active intervention was advised for the microadenoma. He was diagnosed to have HPA axis suppression which was attributed to the prolonged use of topical betamethasone ointment. In view of worsening exudative fluid in OU, the patient was started on oral eplerenone at a dose of 25 mg/day. The endocrinologist advised oral hydrocortisone 5 mg/day to maintain physiological levels of stress hormones needed to counter day-to-day stresses.
Following the initiation of oral eplerenone and hydrocortisone, the patient showed progressive improvement in BCVA with gradual decrease in the subretinal fluid, and slow but continuous resolution of the exudative retinal detachment in OD. At 3-month follow-up (after 6 weeks of therapy with oral eplerenone), his BCVA improved to 6/36 in OD and 6/18 in OS [ Fig. 4 ].
At 6-month follow-up (after 12 weeks of therapy with oral eplerenone), his BCVA had improved to 6/24 (parts) in OD and 6/12 in OS with complete resolution of the exudative retinal detachment in OD and total resolution of subretinal fluid in OS [ Fig. 5 ]. The endocrinologist has advised tapering of oral hydrocortisone based on the results of repeat laboratory hormone levels.
Discussion
The pathology of CSC involves development of serous retinal detachment, RPE abnormalities, choroidal hyperpermeability, and relative choriocapillaris ischemia because of a dysfunction involving the blood-retinal barriers and insufficient salt pumps at the RPE-Bruch's membrane. [1, 3, 6] Patients with an increase in endogenous corticosteroids in conditions such as Cushing's syndrome, [7] pregnancy, [8] and steroid producing tumors [9] also develop features of CSC, especially fibrinous type or with large bullous exudative retinal detachments. [10, 11] Corticosteroid-related CSC can develop due to multifactorial effects of this hormone leading to increased RPE leakage, RPE cell apoptosis, and alterations in ion transport across RPE cells. [12] While nearly 30% of patients may have HPA axis dysfunction with elevation of serum cortisol levels, [5, 7] our patient demonstrated suppression of HPA axis and low serum cortisol levels along with other abnormalities such as low serum testosterone, which is unexpected in patients with CSC. It may be postulated that our patient developed HPA axis suppression after prolonged use of topical betamethasone ointment. [13] To maintain the normal levels of serum cortisol in the body to overcome day-to-day stresses, the patient was advised low physiological doses (5 mg) of oral hydrocortisone.
Our patient developed CSC because of possible exogenous corticosteroid exposure 2 years ago (before presentation to our center). Subsequently, due to intermittent corticosteroid ointment use, he developed HPA axis suppression leading to low levels of serum cortisol. The exact pathogenesis of CSC with low serum cortisol levels is unclear in our case. It is likely that CSC may occur as a result of myriad of endocrinological abnormalities including normal or low levels of serum cortisol. Thyroid-associated ophthalmopathy is well-known to occur in hypothyroid patients in 7.5% of cases, due to possible autoimmune mechanisms and other pathways which are not well-elucidated. [14, 15] It may be possible that certain pathways, including relative mineralocorticoid excess, may lead to development of CSC in our patient.
Eplerenone, a mineralocorticoid antagonist, has been recently explored in the management of chronic CSC. [16] In the first published report of use of eplerenone by Zhao et al., [17] 25 mg/day for 1 week followed by 50 mg/day led to rapid resolution of subretinal fluid and improvement in visual acuity. In a comparative study which included patients with bilateral chronic CSC with exudative retinal detachment in one eye and no exudative fluid in the fellow eye (n = 28), [18] treatment was initiated with 50 mg/day eplerenone for 3 months. There was a significant decrease in the macular and choroidal thickness, and resolution of subretinal fluid at 6 months. The effect was more pronounced in the eye with exudative detachment, similar to our patient. A number of retrospective and prospective series on the use of eplerenone have been published since. [19] [20] [21] [22] [23] The highlight of our case is the documentation of comprehensive hormonal profile which revealed low serum cortisol and other abnormalities. It may be possible to detect such abnormally low levels of cortisol in other cases of CSC if specifically investigated, especially among those patients who respond to eplerenone. Our case showed rapid and complete resolution of subretinal fluid within a period of 8-10 weeks with the help of eplerenone [ Figs. 1 and 4 ]. From a stage where the retinal detachment was so bullous that even surgical intervention was considered [ Fig. 3 ], our patient dramatically responded to only 25 mg/day eplerenone. While our case is able to successfully demonstrate the efficacy of eplerenone, it is very challenging to ascertain the pathophysiology of CSC with low serum cortisol based on our single case. It may be possible that a thorough investigation after pooling such cases, if any, may lead us to the pathogenesis of the disease in the future.
Conclusion
In summary, our case represents a rare association of CSC with low serum cortisol levels which responded to treatment with oral mineralocorticoid antagonist (eplerenone) along with physiological doses of hydrocortisone.
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